adaptive radiotherapy bladder cancer

Carcinoma Transitional Cell/epidemiology/*surgery *Cystectomy Humans Kidney Neoplasms/*epidemiology Neoplasms Second Primary/*epidemiology Ureteral Neoplasms/*epidemiology Urethral Neoplasms/*epidemiology Urinary Bladder Neoplasms/*surgery Bladder cancer Radical cystectomy Recurrence Remnant Upper urinary tract Urethra Urothelium including specific financial interests and relationships and affiliations relevant to the subject matter or materials discussed in the manuscript (eg employment/affiliation grants or funding consultancies honoraria stock ownership or options expert testimony royalties or patents filed received or pending) are the following: None.

Adenocarcinoma/epidemiology/*pathology/surgery Cystectomy/*methods Digital Rectal Examination Humans Incidental Findings Male Neoplasm Recurrence Local/pathology Prognosis Prostate/pathology Prostate-Specific Antigen Prostatectomy/*methods Prostatic Neoplasms/epidemiology/*pathology/surgery Survival Rate Urinary Bladder Neoplasms/*surgery bladder neoplasms cystectomy prostatectomy prostatic neoplasms

bladder cancer chemotherapy cystectomy muscle-invasive systematic review of interest.

Carcinogens Environmental/adverse effects Gene-Environment Interaction Humans Incidence Occupational Exposure/adverse effects Prevalence Risk Assessment Risk Factors Smoking/adverse effects/epidemiology Time Factors Urinary Bladder Neoplasms/diagnosis/*epidemiology/genetics/mortality Bladder Cancer Epidemiology Urothelial

Cisplatin/*therapeutic use Female Humans Male Neoadjuvant Therapy/*methods Urinary Bladder/drug effects/pathology Urinary Bladder Neoplasms/*drug therapy/pathology

Radical cystectomy metastatic bladder cancer non-organ confined bladder cancer

*Body Mass Index Cohort Studies Humans Odds Ratio Prospective Studies Risk Factors Urinary Bladder Neoplasms/*epidemiology/*etiology bladder cancer body mass index dose-response meta-analysis risk

Administration Intravesical Aged Aged 80 and over BCG Vaccine/*therapeutic use Biopsy Needle Disease-Free Survival Female Humans Immunohistochemistry Immunotherapy/*methods In Situ Hybridization Fluorescence Male Middle Aged Neoplasm Recurrence Local/mortality/*pathology Predictive Value of Tests Prognosis Risk Assessment Survival Analysis Treatment Outcome Urinary Bladder Neoplasms/mortality/pathology/*therapy Bcg Bladder cancer Immunotherapy Personalized therapy Response prediction

Arylamine N-Acetyltransferase/*genetics Genotype Humans Isoenzymes/*genetics Phenotype Polymorphism Genetic Urinary Bladder Neoplasms/*enzymology/*genetics N-Acetyltransferase Nat1 genetic polymorphism meta-analysis smoking systematic review urinary bladder cancer

bladder cancer circulating tumor cells (CTCs) meta-analysis prognosis urothelial cancer

Chemoradiotherapy Adjuvant Combined Modality Therapy Cystectomy/*methods Disease-Free Survival Humans Muscles/pathology Neoadjuvant Therapy Neoplasm Invasiveness Treatment Outcome Urinary Bladder Neoplasms/pathology/*therapy Bladder cancer Radical cystectomy Trimodal therapy

Alleles Case-Control Studies *Genetic Predisposition to Disease Genotype Glutathione Transferase/*genetics Humans Odds Ratio *Polymorphism Genetic Publication Bias Risk Urinary Bladder Neoplasms/epidemiology/*genetics Gstm1 Gstt1 bladder cancer polymorphism

Adult Aged Aged 80 and over Female Humans *Magnetic Resonance Imaging Male Middle Aged *Neoplasm Staging/methods/standards Urinary Bladder Neoplasms/*diagnostic imaging bladder cancer diagnostic accuracy magnetic resonance imaging staging systematic review

Biomarkers Tumor/*urine Cystoscopy/methods *DNA Methylation Humans Urinary Bladder Neoplasms/*diagnosis/urine biomarkers methylation molecular diagnostics neoplasms urinary bladder urine analysis

Biomarkers Tumor/*urine Fibronectins/*urine Humans Prognosis Urinary Bladder Neoplasms/*diagnosis/urine Biomarker Bladder cancer Diagnosis Meta-analysis Urine fibronectin standards of institutional and international research committee this article is based on previous published studies thus it does not contain any studies with human participants or animals. CONSENT FOR PUBLICATION: Not applicable. COMPETING INTERESTS: The authors declare that they have no competing interests. PUBLISHER’S NOTE: Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Epirubicin/*therapeutic use Female Humans Immunotherapy/*methods Male Mitomycin/*therapeutic use *Mycobacterium bovis Urinary Bladder Neoplasms/immunology/pathology/*therapy Bacillus Calmette–Guérin Consistency Epirubicin Gemcitabine Heterogeneity Interferon-Alpha Intravesical instillation therapies Mitomycin C Pairwise/network meta-analysis Tumor progression Tumor recurrence

biomarkers ‹› urine bladder cancer ‹› miRNA ‹› microRNA ‹›

Aged *Coffee Cohort Studies Female Follow-Up Studies Humans Incidence Japan/epidemiology Male Middle Aged Prospective Studies Risk Factors Surveys and Questionnaires Urinary Bladder Neoplasms/diagnosis/*epidemiology/*prevention & control

Biomarkers Tumor *Cystoscopy *Cytodiagnosis Early Detection of Cancer Humans Prospective Studies Reproducibility of Results Retrospective Studies Sensitivity and Specificity Urinary Bladder Neoplasms/complications/*diagnosis/pathology Urinary Bladder Neurogenic/*complications (MeSH): neurogenic bladder bladder cancer cystoscopy screening urinary cytology